Trump’s tariff threat on generic drugs: Why this matters for Indian pharma companies
360° Perspective Analysis
Deep-dive into Geography, Polity, Economy, History, Environment & Social dimensions — AI-powered, on-demand
Context
Former US President Donald Trump has proposed increasing tariffs on generic drugs imported into the US by 100% after two years, and 200% thereafter, to compel companies to manufacture within the United States. This protectionist threat is significant for India, as the US is its largest pharmaceutical export market, leading Indian pharma giants to increase their outbound investments and acquisitions in the US to bypass potential trade barriers.
UPSC Perspectives
Economic
This development highlights the economic concept of protectionism, where a country uses tariffs to shield domestic industries from foreign competition. The US has utilized various legal instruments for this, including the and Section 232 of the , which invokes national security to justify tariffs. For India, the stakes are high: the US accounts for roughly 40% of India's pharmaceutical exports, and 90% of these are generic drugs. A steep tariff hike would significantly erode the competitive advantage of Indian generics, which typically operate on very thin margins. Consequently, this threat is driving a surge in Foreign Direct Investment (FDI) outflows from India to the US. This is evidenced by major acquisitions like purchasing Organon & Co. By establishing manufacturing bases within the US (reshoring or nearshoring), Indian companies aim to circumvent these proposed tariffs and secure continued access to the world's largest consumer market. However, relocating such large-scale production is complex and expensive, particularly given the reliance on global supply chains for Active Pharmaceutical Ingredients (APIs), largely sourced from India and China.
International Relations
The proposed tariffs reflect a broader shift in US trade policy towards economic nationalism and 'America First' policies, significantly impacting bilateral trade relations. While often framed as national security measures (using Section 232), trade experts view these threats as coercive tactics to force global pharmaceutical companies to invest in the US, especially ahead of elections. This dynamic illustrates the increasing intersection of geopolitics and trade, where economic levers are used to achieve domestic political objectives. For India, this presents a challenge to its 'Pharmacy of the World' status. The must navigate these uncertainties, potentially seeking exemptions or negotiating bilateral agreements to protect its export interests. The situation underscores the vulnerability of export-dependent sectors to sudden shifts in the trade policies of major partner countries and highlights the need for market diversification.
Governance
From a domestic US governance perspective, implementing these tariffs presents a complex policy dilemma. While the goal is to boost domestic manufacturing and job creation, the practical reality of the generic drug market suggests potential negative consequences for consumers. Generic medicines are crucial for keeping healthcare costs manageable. As highlighted by the , building a fully domestic supply chain in the US would require massive investment. Because generics operate on low profit margins, the increased costs of domestic manufacturing, coupled with the reliance on imported APIs, would almost certainly lead to higher drug prices for US citizens. This highlights the tension between industrial policy (promoting domestic manufacturing) and public health policy (ensuring affordable access to medicines). The 's role in approving foreign manufacturing sites, which many Indian companies currently rely on, adds another layer of regulatory complexity to this issue.